Biocept to Present at the 28th Annual ROTH Conference

SAN DIEGO, March 7, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at the 28^th Annual ROTH Conference on Monday, March 14, 2016, at 8:30 a.m. Pacific time (11:30 a.m. Eastern time).  The conference is being held at The Ritz Carlton Laguna Niguel hotel in Dana Point, Calif.

A live webcast of the corporate presentation will be available on the Company's website at ir.biocept.com. A replay of the presentations will be available for 90 days.

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (ctDNA). Biocept currently offers assays for prostate cancer, gastric cancer, breast cancer, lung cancer, colorectal cancer and melanoma, and plans to introduce CLIA-validated tests for other solid tumors in the near term. For additional information, please visit www.biocept.com.

Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-28th-annual-roth-conference-300231364.html

SOURCE Biocept, Inc.